MOUNTAINEER: A Homegrown Story of Survival and Promise
Global biotech company Seagen Inc. announced positive topline results last month of a pivotal phase 2 clinical trial (called MOUNTAINEER) of tucatinib in combination with trastuzumab in HER2-positive metastatic colorectal cancer. Both drugs are used in breast cancer, a type of cancer where HER2 amplification is common. HER2 amplification is uncommon, however, in colorectal cancer.
Strickler will present the full data at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer in Barcelona, Spain — to be held June 29 through July 2, 2022. According to Seagen, "data from this trial will form the basis of a planned supplemental New Drug Application to the FDA under the FDA’s Accelerated Approval Program."
(UPDATE 7.27.22) Coverage of MOUNTAINEER results presentation at ESMO
Dr. Strickler on the Rationale of Examining Tucatinib with Trastuzumab in HER2+ CRC AND Tucatinib Plus Trastuzumab Induces Durable Tumor Response in HER2+ mCRC AND Dr. Strickler on the Efficacy of Tucatinib/ Trastuzumab in HER2+ Colorectal Cancer (OncLive)
Tucatinib/Trastuzumab Combo Elicits Tumor Response in HER2+ mCRC (Oncology Nursing News)
Seagen releases data from Tukysa pivotal trial in HER2+ mCRC (The Pharma Letter)